1Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism [ J ]. Nat Rev Genet, 2006,7(8) :606-619. 被引量：1
2Carver BS, Chapinski C, Wongvipat J, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer[ J]. Cancer Cell ,2011,19( 5 ) :575-586. 被引量：1
3Engelman, JA,Chen L,Tan X,et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers[ J]. Nat Med ,2008,14 ( 12 ) : 1351-1356. 被引量：1
4Zhao L, Vogt PK. Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms [ J ]. Proc Natl Acad USA, 2008, 105 ( 7 ) : 2652-2657. 被引量：1
5Courtney KD, Corcoran RB, Engelman JA, et al. The PI3K pathway as drug target in human cancer [ J ]. J Clini Oncol, 2010, 28 ( 6 ) : 1075-1083. 被引量：1
6Karakas B, Bachman KE, Park BH. Mutation of the PIK3CA oncogene in human cancers[ J]. Br J Cancer,2006,94(4) :455-459. 被引量：1
7SamuelsY, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers[ J]. Science,2004,304(5670) :554. 被引量：1
8Liu P, Cheng H, Roberts TM, et al. Targeting the phosphoinositide 3- kinase pathway in cancer [ J ]. Nat Rev Drug Discov, 2009, 8 ( 8 ) : 627 -644. 被引量：1
9Vanhaesebroeck B, Guilermet-Guibert J, Granpera M, et al. The emerging mechanisms of isoform-specific PI3 K signalling [ J ]. Nat Rev Mol Cell Bio ,2010,11 (5) :329-341. 被引量：1
10Bussink J, van der Kogel A J, Kaanders JH. Activation of the PI3-K/Akt pathway andimplications for radioresistance mechanisms in head and neck cancer [ J ]. Lancet Oncol,2008,9 ( 3 ) :288-296. 被引量：1
